Egypt-based biotech startup Reme-D has secured a $500,000 investment from the Global Innovation Fund (GIF). The capital will be used to expand the production and geographical reach of its room-temperature stable molecular diagnostic kits, targeting regions where traditional cold-chain logistics frequently fail.
Born out of a government-backed consortium to address PCR test shortages during the early days of the Covid-19 pandemic, Reme-D formally launched in 2022. Founded by nanotechnology researcher Salma Tammam, the company has since shifted its focus from pandemic response to addressing broader diagnostic deficits across the continent.
Overcoming the cold-chain barrier
Traditional PCR (polymerase chain reaction) test kits require strict temperature control. In regions with unreliable power infrastructure, this dependency leads to degraded enzymes, loss of reagent potency, and significant waste. The World Health Organization estimates that only about half of hospitals in sub-Saharan Africa have reliable electricity.
Reme-D mitigates this through advanced freeze-drying methods and nanotechnology, allowing its chemical reagents to remain stable at room temperature for months.
“This wasn’t just a technical achievement,” says Tammam. “It was about making molecular diagnostics truly accessible in resource-limited settings.”
The startup reports that its localized manufacturing and cold-chain-independent design reduce diagnostic costs by up to 40% compared to imported alternatives, while maintaining high clinical accuracy (95% sensitivity and 98% specificity). Furthermore, the kits are optimised to detect local pathogen strains that are often overlooked by global manufacturers.
Reme-D at a glance
- Founded: 2022
- Founder: Salma Tammam
- Product: Refrigeration-free PCR testing kits for over 30 diseases.
- Traction: Testing approximately 50,000 patients monthly across 92 hospitals and labs in Egypt; over 500,000 patients tested to date.
- Current Markets: Egypt, Iraq, Sudan, Kenya. Preliminary use in Nigeria and Libya.
- Total Funding: Prior to the $500k GIF investment, the startup raised approximately $1m, including backing from the Oman Technology Fund.
Expanding blood bank screening
Early adoption of Reme-D’s technology has been particularly notable in regional blood banks. Historically, these facilities screened donated units using Chemiluminescent Immunoassays (CLIA), followed by PCR confirmation for positive results — a two-step process that causes delays.
By utilizing Reme-D’s more affordable PCR systems, blood banks have cut the screening window period by 70%, allowing every donated unit to be tested directly and rapidly with molecular diagnostics.
Production bottlenecks and regulatory hurdles
Despite its commercial traction, Reme-D faces operational and regulatory scaling challenges. While its Egyptian production facility has the capacity to manufacture up to 12 million tests per month, current packaging limitations cap actual output at 130,000 units. To address this bottleneck, Tammam plans to expand the facility fourfold by the second quarter of 2026.
Market entry is further complicated by fragmented regulatory frameworks. Medical device approval processes vary drastically between African nations, and many domestic frameworks heavily favor established Western manufacturers over localized biotech producers.
Tammam has frequently encountered investor skepticism regarding the viability of African biotech. “The most difficult experience lies at the intersection of global stereotypes and the harsh reality that African countries aren’t typically known for producing biotech products,” she notes, recalling instances where potential partners doubted the validity of a diagnostic test not developed in the West.
Winning the Bayer Foundation Women Empowerment Award — which included a €25,000 grant and selection from a pool of over 1,700 global applicants — has served as necessary external validation to counter some of this institutional skepticism.
What’s next
With the new injection of capital from the Global Innovation Fund, Reme-D is preparing for a full commercial launch in Nigeria and Libya. The company is also expanding its research and development pipeline beyond infectious diseases, developing diagnostic solutions for genetic disorders, cancer, and maternal health — areas where room-temperature stability remains a critical advantage.